DEXCOM, INC. Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
DEXCOM, INC. (DXCM) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt of $289.40 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-02-14.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt · last filed 2022-02-14
- DEXCOM, INC. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2020-12-31 was $0.00.
- DEXCOM, INC. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2020-09-30 was $0.00.
- DEXCOM, INC. adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2020-06-30 was $289.40M.
- DEXCOM, INC. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2020 was $289.40M.
- DEXCOM, INC. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2018 was $171.60M, a 143.06% increase from fiscal 2017.
- DEXCOM, INC. adjustments to additional paid in capital, equity component of convertible debt for fiscal 2017 was $70.60M.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 3 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 6 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 9 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 12 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 12 month as first filed |
|---|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-14 | $0.00 derived: sum of 2 quarters · filed 2022-02-14 | $289.40M derived: sum of 3 quarters · filed 2022-02-14 | $289.40M 10-K · filed 2022-02-14 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $289.40M derived: sum of 2 quarters · filed 2021-10-28 | $289.40M 10-Q · filed 2021-10-28 | ||
| 2020-06-30 | $289.40M 10-Q · filed 2021-07-29 | $289.40M 10-Q · filed 2021-07-29 | |||
| 2018-12-31 | $171.60M 10-K · filed 2021-02-11 | -$218.90M 10-K · filed 2019-02-21 | |||
| 2017-12-31 | $70.60M 10-K · filed 2018-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WEST PHARMACEUTICAL SERVICES INC (WST) | United States | $26.288B | 43.14 |
| BECTON DICKINSON & CO (BDX) | United States | $48.834B | 43.79 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |